Improved local and systemic anti-tumor efficacy for irreversible electroporation in immunocompetent versus immunodeficient mice. Neal, R. E., Rossmeisl, J. H., Robertson, J. L., Arena, C. B., Davis, E. M., Singh, R. N., Stallings, J., & Davalos, R. V. PLoS One, 8(5):e64559, 2013. 1932-6203 Neal, Robert E 2nd Rossmeisl, John H Jr Robertson, John L Arena, Christopher B Davis, Erica M Singh, Ravi N Stallings, Jonathan Davalos, Rafael V K99 CA154006/CA/NCI NIH HHS/United States R00 CA154006/CA/NCI NIH HHS/United States K99CA154006/CA/NCI NIH HHS/United States Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. United States 2013/05/30 PLoS One. 2013 May 24;8(5):e64559. doi: 10.1371/journal.pone.0064559. Print 2013.doi abstract bibtex Irreversible electroporation (IRE) is a non-thermal focal ablation technique that uses a series of brief but intense electric pulses delivered into a targeted region of tissue, killing the cells by irrecoverably disrupting cellular membrane integrity. This study investigates if there is an improved local anti-tumor response in immunocompetent (IC) BALB/c versus immunodeficient (ID) nude mice, including the potential for a systemic protective effect against rechallenge. Subcutaneous murine renal carcinoma tumors were treated with an IRE pulsing protocol that used 60% of the predicted voltage required to invoke complete regressions in the ID mice. Tumors were followed for 34 days following treatment for 11 treated mice from each strain, and 7 controls from each strain. Mouse survival based on tumor burden and the progression-free disease period was substantially longer in the treated IC mice relative to the treated ID mice and sham controls for both strains. Treated IC mice were rechallenged with the same cell line 18 days after treatment, where growth of the second tumors was shown to be significantly reduced or prevented entirely. There was robust CD3+ cell infiltration in some treated BALB/C mice, with immunocytes focused at the transition between viable and dead tumor. There was no difference in the low immunocyte presence for untreated tumors, nude mice, and matrigel-only injections in both strains. These findings suggest IRE therapy may have greater therapeutic efficacy in immunocompetent patients than what has been suggested by immunodeficient models, and that IRE may invoke a systemic response beyond the targeted ablation region.
@article{RN202,
author = {Neal, R. E., 2nd and Rossmeisl, J. H., Jr. and Robertson, J. L. and Arena, C. B. and Davis, E. M. and Singh, R. N. and Stallings, J. and Davalos, R. V.},
title = {Improved local and systemic anti-tumor efficacy for irreversible electroporation in immunocompetent versus immunodeficient mice},
journal = {PLoS One},
volume = {8},
number = {5},
pages = {e64559},
note = {1932-6203
Neal, Robert E 2nd
Rossmeisl, John H Jr
Robertson, John L
Arena, Christopher B
Davis, Erica M
Singh, Ravi N
Stallings, Jonathan
Davalos, Rafael V
K99 CA154006/CA/NCI NIH HHS/United States
R00 CA154006/CA/NCI NIH HHS/United States
K99CA154006/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
United States
2013/05/30
PLoS One. 2013 May 24;8(5):e64559. doi: 10.1371/journal.pone.0064559. Print 2013.},
abstract = {Irreversible electroporation (IRE) is a non-thermal focal ablation technique that uses a series of brief but intense electric pulses delivered into a targeted region of tissue, killing the cells by irrecoverably disrupting cellular membrane integrity. This study investigates if there is an improved local anti-tumor response in immunocompetent (IC) BALB/c versus immunodeficient (ID) nude mice, including the potential for a systemic protective effect against rechallenge. Subcutaneous murine renal carcinoma tumors were treated with an IRE pulsing protocol that used 60% of the predicted voltage required to invoke complete regressions in the ID mice. Tumors were followed for 34 days following treatment for 11 treated mice from each strain, and 7 controls from each strain. Mouse survival based on tumor burden and the progression-free disease period was substantially longer in the treated IC mice relative to the treated ID mice and sham controls for both strains. Treated IC mice were rechallenged with the same cell line 18 days after treatment, where growth of the second tumors was shown to be significantly reduced or prevented entirely. There was robust CD3+ cell infiltration in some treated BALB/C mice, with immunocytes focused at the transition between viable and dead tumor. There was no difference in the low immunocyte presence for untreated tumors, nude mice, and matrigel-only injections in both strains. These findings suggest IRE therapy may have greater therapeutic efficacy in immunocompetent patients than what has been suggested by immunodeficient models, and that IRE may invoke a systemic response beyond the targeted ablation region.},
keywords = {Animals
Cell Line, Tumor
*Electroporation
Female
Immunocompromised Host
Mice
Mice, Inbred BALB C
Mice, Nude
Neoplasms/*immunology/mortality/*pathology
Tumor Burden/immunology},
ISSN = {1932-6203},
DOI = {10.1371/journal.pone.0064559},
year = {2013},
type = {Journal Article}
}
Downloads: 0
{"_id":"35B9Zh6Rsv22P643b","bibbaseid":"neal-rossmeisl-robertson-arena-davis-singh-stallings-davalos-improvedlocalandsystemicantitumorefficacyforirreversibleelectroporationinimmunocompetentversusimmunodeficientmice-2013","downloads":0,"creationDate":"2019-03-08T20:39:38.695Z","title":"Improved local and systemic anti-tumor efficacy for irreversible electroporation in immunocompetent versus immunodeficient mice","author_short":["Neal, R. E.","Rossmeisl, J. H.","Robertson, J. L.","Arena, C. B.","Davis, E. M.","Singh, R. N.","Stallings, J.","Davalos, R. V."],"year":2013,"bibtype":"article","biburl":"https://bibbase.org/network/files/bdNBTZRXTsoHCgpbh","bibdata":{"bibtype":"article","type":"Journal Article","author":[{"propositions":[],"lastnames":["Neal"],"firstnames":["R.","E."],"suffixes":["2nd"]},{"propositions":[],"lastnames":["Rossmeisl"],"firstnames":["J.","H."],"suffixes":["Jr."]},{"propositions":[],"lastnames":["Robertson"],"firstnames":["J.","L."],"suffixes":[]},{"propositions":[],"lastnames":["Arena"],"firstnames":["C.","B."],"suffixes":[]},{"propositions":[],"lastnames":["Davis"],"firstnames":["E.","M."],"suffixes":[]},{"propositions":[],"lastnames":["Singh"],"firstnames":["R.","N."],"suffixes":[]},{"propositions":[],"lastnames":["Stallings"],"firstnames":["J."],"suffixes":[]},{"propositions":[],"lastnames":["Davalos"],"firstnames":["R.","V."],"suffixes":[]}],"title":"Improved local and systemic anti-tumor efficacy for irreversible electroporation in immunocompetent versus immunodeficient mice","journal":"PLoS One","volume":"8","number":"5","pages":"e64559","note":"1932-6203 Neal, Robert E 2nd Rossmeisl, John H Jr Robertson, John L Arena, Christopher B Davis, Erica M Singh, Ravi N Stallings, Jonathan Davalos, Rafael V K99 CA154006/CA/NCI NIH HHS/United States R00 CA154006/CA/NCI NIH HHS/United States K99CA154006/CA/NCI NIH HHS/United States Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. United States 2013/05/30 PLoS One. 2013 May 24;8(5):e64559. doi: 10.1371/journal.pone.0064559. Print 2013.","abstract":"Irreversible electroporation (IRE) is a non-thermal focal ablation technique that uses a series of brief but intense electric pulses delivered into a targeted region of tissue, killing the cells by irrecoverably disrupting cellular membrane integrity. This study investigates if there is an improved local anti-tumor response in immunocompetent (IC) BALB/c versus immunodeficient (ID) nude mice, including the potential for a systemic protective effect against rechallenge. Subcutaneous murine renal carcinoma tumors were treated with an IRE pulsing protocol that used 60% of the predicted voltage required to invoke complete regressions in the ID mice. Tumors were followed for 34 days following treatment for 11 treated mice from each strain, and 7 controls from each strain. Mouse survival based on tumor burden and the progression-free disease period was substantially longer in the treated IC mice relative to the treated ID mice and sham controls for both strains. Treated IC mice were rechallenged with the same cell line 18 days after treatment, where growth of the second tumors was shown to be significantly reduced or prevented entirely. There was robust CD3+ cell infiltration in some treated BALB/C mice, with immunocytes focused at the transition between viable and dead tumor. There was no difference in the low immunocyte presence for untreated tumors, nude mice, and matrigel-only injections in both strains. These findings suggest IRE therapy may have greater therapeutic efficacy in immunocompetent patients than what has been suggested by immunodeficient models, and that IRE may invoke a systemic response beyond the targeted ablation region.","keywords":"Animals Cell Line, Tumor *Electroporation Female Immunocompromised Host Mice Mice, Inbred BALB C Mice, Nude Neoplasms/*immunology/mortality/*pathology Tumor Burden/immunology","issn":"1932-6203","doi":"10.1371/journal.pone.0064559","year":"2013","bibtex":"@article{RN202,\n author = {Neal, R. E., 2nd and Rossmeisl, J. H., Jr. and Robertson, J. L. and Arena, C. B. and Davis, E. M. and Singh, R. N. and Stallings, J. and Davalos, R. V.},\n title = {Improved local and systemic anti-tumor efficacy for irreversible electroporation in immunocompetent versus immunodeficient mice},\n journal = {PLoS One},\n volume = {8},\n number = {5},\n pages = {e64559},\n note = {1932-6203\nNeal, Robert E 2nd\nRossmeisl, John H Jr\nRobertson, John L\nArena, Christopher B\nDavis, Erica M\nSingh, Ravi N\nStallings, Jonathan\nDavalos, Rafael V\nK99 CA154006/CA/NCI NIH HHS/United States\nR00 CA154006/CA/NCI NIH HHS/United States\nK99CA154006/CA/NCI NIH HHS/United States\nJournal Article\nResearch Support, N.I.H., Extramural\nResearch Support, Non-U.S. Gov't\nResearch Support, U.S. Gov't, Non-P.H.S.\nUnited States\n2013/05/30\nPLoS One. 2013 May 24;8(5):e64559. doi: 10.1371/journal.pone.0064559. Print 2013.},\n abstract = {Irreversible electroporation (IRE) is a non-thermal focal ablation technique that uses a series of brief but intense electric pulses delivered into a targeted region of tissue, killing the cells by irrecoverably disrupting cellular membrane integrity. This study investigates if there is an improved local anti-tumor response in immunocompetent (IC) BALB/c versus immunodeficient (ID) nude mice, including the potential for a systemic protective effect against rechallenge. Subcutaneous murine renal carcinoma tumors were treated with an IRE pulsing protocol that used 60% of the predicted voltage required to invoke complete regressions in the ID mice. Tumors were followed for 34 days following treatment for 11 treated mice from each strain, and 7 controls from each strain. Mouse survival based on tumor burden and the progression-free disease period was substantially longer in the treated IC mice relative to the treated ID mice and sham controls for both strains. Treated IC mice were rechallenged with the same cell line 18 days after treatment, where growth of the second tumors was shown to be significantly reduced or prevented entirely. There was robust CD3+ cell infiltration in some treated BALB/C mice, with immunocytes focused at the transition between viable and dead tumor. There was no difference in the low immunocyte presence for untreated tumors, nude mice, and matrigel-only injections in both strains. These findings suggest IRE therapy may have greater therapeutic efficacy in immunocompetent patients than what has been suggested by immunodeficient models, and that IRE may invoke a systemic response beyond the targeted ablation region.},\n keywords = {Animals\nCell Line, Tumor\n*Electroporation\nFemale\nImmunocompromised Host\nMice\nMice, Inbred BALB C\nMice, Nude\nNeoplasms/*immunology/mortality/*pathology\nTumor Burden/immunology},\n ISSN = {1932-6203},\n DOI = {10.1371/journal.pone.0064559},\n year = {2013},\n type = {Journal Article}\n}\n\n","author_short":["Neal, R. E.","Rossmeisl, J. H.","Robertson, J. L.","Arena, C. B.","Davis, E. M.","Singh, R. N.","Stallings, J.","Davalos, R. V."],"key":"RN202","id":"RN202","bibbaseid":"neal-rossmeisl-robertson-arena-davis-singh-stallings-davalos-improvedlocalandsystemicantitumorefficacyforirreversibleelectroporationinimmunocompetentversusimmunodeficientmice-2013","role":"author","urls":{},"keyword":["Animals Cell Line","Tumor *Electroporation Female Immunocompromised Host Mice Mice","Inbred BALB C Mice","Nude Neoplasms/*immunology/mortality/*pathology Tumor Burden/immunology"],"metadata":{"authorlinks":{}},"downloads":0},"search_terms":["improved","local","systemic","anti","tumor","efficacy","irreversible","electroporation","immunocompetent","versus","immunodeficient","mice","neal","rossmeisl","robertson","arena","davis","singh","stallings","davalos"],"keywords":["animals cell line","tumor *electroporation female immunocompromised host mice mice","inbred balb c mice","nude neoplasms/*immunology/mortality/*pathology tumor burden/immunology"],"authorIDs":[],"dataSources":["D4zENc4BfFNBwSYYJ","ZPLjameRikygaiM9B","3XfNmZkLe6o8CvECW","fJQsxtBoqymHQG6tL","LzxgEApraxMPkLTMn","Z2THpXfLYEJf3CB8p"]}